SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a foc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback